J&J buys into spine test firm
This article was originally published in The Gray Sheet
Johnson & Johnson leads a $15.3 million financing round and enters a strategic collaboration with Axial Biotech to accelerate the start-up's development of a genetic test to pre-symptomatically predict which cases of scoliosis, or abnormal curvature of the spine, are likely to progress and require intervention, firms announce March 27. Axial hopes to launch the first-of-its-kind test in late 2008, and estimates a U.S. market size of $180 million. The Raynham, Mass. firm also is developing minimally invasive devices for spine surgery...
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.